VANCOUVER, Washington, June 01, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5 antagonist with potential multiple therapeutic
Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
April 19, 2021 06:00 ET | Source: CytoDyn Inc. CytoDyn Inc. Vancouver, Washington, UNITED STATES
CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release
VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE)
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company ), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today former President of the Philippines, Joseph Estrada, was administered leronlimab under Compassionate Special Permit (CSP), among other medication, as a therapeutic for COVID-19. Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular ho
CytoDyn Inc submits manufacturing section of interim order application for leronlimab as coronavirus (COVID-19) treatment to Health Canada proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to .
CytoDyn Inc.April 15, 2021 GMT
Under Compassionate Special Permit (CSP) in Philippines, CytoDyn is well positioned to generate significant revenues
VANCOUVER, Washington., April 15, 2021 (GLOBE NEWSWIRE) CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has executed an exclusive supply and distribution agreement with Chiral Pharma Corporation to supply up to 200,000 vials of leronlimab to critically ill COVID-19 patients in the Philippines under CSP authorizations. This agreement will accelerate the delivery of leronlimab upon an expanded authorization under CSP.